A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Part of paid clinical trials in Mobile, Alabama.

Sponsor
Bristol-Myers Squibb
Study ID
NCT05552976
Phase
PHASE3
Status
Active Not Recruiting

Conditions

  • Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Mezigdomide — DRUG
    Specified dose on specified days
  • Carfilzomib — DRUG
    Specified dose on specified days
  • Dexamethasone — DRUG
    Specified dose on specified days

Study Details

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

Key Dates

Start date
Jan 10, 2023
Status verified
Mar 2026
Primary completion
Jul 18, 2026
Completion
Jul 25, 2029

Study Design

Enrollment
606 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)
  • Active Comparator: Kd (Carfilzomib + Dexamethasone)

Primary Outcome Measure

Progression-free Survival (PFS) [ Time Frame: Up to approximately 5 years ]

Locations (34)

FacilityCityStateZIPSite coordinators
Local Institution - 0046MobileAlabama36604-
Local Institution - 0005CerritosCalifornia90703-
Local Institution - 0190IrvineCalifornia92618-
Local Institution - 0187Los AngelesCalifornia90017-
Local Institution - 0344Santa RosaCalifornia95403-
Local Institution - 0339StocktonCalifornia95204-
Local Institution - 0279NewarkDelaware19713-
Local Institution - 0341Fort MyersFlorida33901-
Local Institution - 0342St. PetersburgFlorida33705-
Local Institution - 0340West Palm BeachFlorida33401-
Local Institution - 0291AtlantaGeorgia30322-
Local Institution - 0348AtlantaGeorgia30303-
Saint Alphonsus Regional Medical CenterBoiseIdaho83706-
Local Institution - 0289AnnapolisMaryland21401-
Local Institution - 0204BostonMassachusetts02215-
Local Institution - 0346MinneapolisMinnesota55404-
Local Institution - 0222Little SilverNew Jersey07739-
Local Institution - 0199The BronxNew York10467-
Local Institution - 0322ClevelandOhio44106-
Local Institution - 0172ColumbusOhio43214-
Local Institution - 0321ProvidenceRhode Island02903-
Local Institution - 0338GreerSouth Carolina29650-
Local Institution - 0349ChattanoogaTennessee37404-
Local Institution - 0323NashvilleTennessee37203-
Local Institution - 0337Fort WorthTexas76104-
Local Institution - 0044HoustonTexas77030-
Local Institution - 0328HoustonTexas77025-
Local Institution - 0195TempleTexas76508-
Local Institution - 0345NorfolkVirginia23502-
Local Institution - 0343RoanokeVirginia24014-
Local Institution - 0006TacomaWashington98405-
Local Institution - 0347VancouverWashington98684-
Local Institution - 0243MorgantownWest Virginia26506-
Local Institution - 0336MarshfieldWisconsin54449-

Find similar trials in Mobile, AL

By research site
Local Institution - 0046· Mobile, ALLocal Institution - 0005· Cerritos, CALocal Institution - 0190· Irvine, CALocal Institution - 0187· Los Angeles, CALocal Institution - 0344· Santa Rosa, CALocal Institution - 0339· Stockton, CA

Related Studies